WHO Endorses Wider Use of GLP-1 Drugs for Obesity Treatment, Cites Supply Concerns
Geneva, Switzerland – The World Health Association (WHO) is recommending the expanded use of GLP-1 receptor agonist drugs – initially developed for diabetes – to combat the global obesity epidemic, but simultaneously warns of potential supply shortages and the risk of counterfeit products. New guidelines released this week advocate for integrated approaches to weight management,emphasizing that medication is not a standalone solution.
The WHO’s recommendations come as demand for these drugs, including semaglutide and liraglutide, surges worldwide. The agency stresses that obesity is a complex, chronic disease involving genetic, biological, social, and environmental factors, requiring complete strategies alongside pharmaceutical interventions. The guidelines are based on scientific evidence, expert reviews, and input from individuals living with obesity, and were developed at the request of Member States.
The WHO advises regulated supply chains, qualified prescribing and strict supervision to ensure patient safety, noting the growing issue of global demand exceeds supply and the circulation of counterfeit or inferior quality products.
the organization reinforces that Medications do not replace integrated approaches such as a balanced diet, regular physical activity and continuous clinical monitoring. Moreover, the WHO emphasizes the need for government actions and changes in the food industry to foster healthier environments and enable early interventions.
The WHO plans to update recommendations as new data emerges and will collaborate with partners in 2026 to prioritize groups with the greatest need.
